Boussard & Gavaudan Holding Ltd (EUR): Estimated NAV(s)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Boussard & Gavaudan Holding Ltd (EUR): Estimated NAV(s)

 

BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares

The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.

 

Close of business 30/11/2016.

 

Estimated Final NAV

 

  Euro Shares Sterling Shares
Estimated Final NAV €  21.8248 £  19.1513
Estimated Final MTD return  -0.06 %  -0.05 %
Estimated Final YTD return  5.67 %  5.84 %
Estimated Final ITD return  118.25 %  91.51 %

 

NAV and returns are calculated net of management and performance fees

 

 

For further information please contact:

 

Boussard & Gavaudan Investment Management, LLP.

Emmanuel Gavaudan +44 (0) 20 3751 5389       Email    : info@bgam-uk.com

 

The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.

This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.

Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.

You should always bear in mind that:

all investment is subject to risk;

results in the past are no guarantee of future results;

the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and

if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice.

 

This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.

 

 

 

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...4e1f4b4110

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

Updated Category News Views 158

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 132

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 152

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 129

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 201

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 94

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
vVARDIS Debuts on NYSE: Transforming Dental Care

Updated Category News Views 92

A New Chapter for Dental Tech Mark your calendars, folks. vVARDIS is stepping onto the New York Stock Exchange (NYSE) stage, waving the banner of NYSE:VVVV. Now, if you've ever sat in that squeaky dental chair feeling the dread of a drill, vVARDIS might just be the new hero in town. Founded by the dynamic duo, Dr. Haley and Dr. Goly Abivardi, they're on a mission to...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 147

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading

Top 5 Most Recently Viewed Articles

Chris Larsen's Strategic XRP Moves: Implications for Investors

Updated Category News Views 333

Overview of Chris Larsen's Recent XRP Transactions Chris Larsen, the influential co-founder and executive chairman of Ripple, has been actively transferring substantial amounts of XRP. Recently, he moved approximately $26 million worth of XRP to Coinbase, one of the most prominent cryptocurrency exchanges. This transfer is part of a larger pattern, contributing to an...

Continue Reading
Mastercard's Options Activity Insights: Market Trends Explored

Updated Category News Views 143

Understanding Mastercard's Recent Options Activity Mastercard is currently in the spotlight as investors engage in noteworthy bearish actions. This indicates a prevailing sentiment among wealthy clients regarding their perspective on the financial giant. Investor Insights on Mastercard Our analysis indicates that certain trades of interest have emerged in the options...

Continue Reading
Discover How CryptoGO Revolutionizes Memecoin Trading

Updated Category News Views 222

Transforming Memecoin Trading for Beginners CryptoGO is a innovative Telegram mini-app crafted specifically to ease the entry of newcomers into the world of memecoin trading. By harnessing the power of the Solana blockchain, CryptoGO revolutionizes how users engage with meme tokens, making the process both accessible and enjoyable. With support for fiat currency, users...

Continue Reading
Pyxis Oncology Updates on Financial Status and Future Plans

Updated Category News Views 325

Latest Developments at Pyxis Oncology Pyxis Oncology, Inc. has recently made headlines with its remarkable progress in the field of oncology. The development and ongoing trials of their innovative therapy, micvotabart pelidotin (MICVO), have shown encouraging preclinical results, highlighting its unique three-pronged mechanism of action. This mechanism enhances anti-tumor...

Continue Reading
Florida’s Cannabis Legalization Gains Momentum with Herald Support

Updated Category News Views 93

Support for Cannabis Legalization Gains Traction The Miami Herald, a notable publication in Florida with a rich history dating back to 1903, has come out strongly in favor of the state's cannabis legalization initiative known as Amendment 3. The proposal will be presented to voters in the upcoming election, marking a significant shift in public policy towards cannabis....

Continue Reading